The results of the phase 3 trial – called the Durable Response Therapy Evaluation for Early or New-Onset Type 1 Diabetes, or DEFEND-1 – sends researchers back to the drawing board in an attempt to use otelixizumab, an antibody created specifically to treat type 1 diabetes and other autoimmune diseases, to help maintain insulin function.
Patients who are being treated with metformin for type 2 diabetes might live longer than other people with the condition who aren’t taking the drug, according to researchers at Cardiff University.
Invokana, a member of the new class of drugs known as sodium glucose co-transporter 2 (SGLT2) inhibitors, was approved in the USA as a single agent in March 2013.
The objective of the study, published in leading diabetes journal Diabetes, Obesity and Metabolism, was to compare all-cause mortality in diabetic patients treated with either sulphonylurea or metformin with matched individuals without diabetes including age, gender, same general practice, smoking status and clinical status criteria.
A group of scientists headed by Dr. Susanne Neschen and Prof. Dr. Martin Hrabě de Angelis from the Helmholtz Zentrum München, partner in the German Center for Diabetes Research, and drug manufacturer Sanofi Aventis, have discovered how metformin and SGLT2 inhibitors can reinforce each other when used together. Read more
The drug – a rosiglitazone-based medicine that controls blood glucose by increased the body’s sensitivity to insulin, so cells and muscles are able to use more for energy, reducing levels in the blood – was off the market in Europe and restricted in the United States for several years due to studies showing the drug […]
Dulaglutide and liraglutide are both glucagon like peptide 1 (GLP-1) agents, require needle injections, and are used mainly in type 2 diabetes. A randomized clinical trial was conducted to compare the two drugs.
A comparison of the effects on A1c between users of once-weekly dulaglutide (made by Eli Lilly and Company) and once-daily liraglutide (sold as Victoza from Novo Nordisk) shows that both drugs have very similar effects.
In a retrospective cohort study, Giovanni Corrao and colleagues from the University of Milano-Bicocca, Italy, evaluated 115,709 individuals who were recently diagnosed with diabetes and treated with statins during the time period of 2003-2004 and followed prospectively until 2010.
Pharma giants Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) have formed the BI-Lilly Diabetes Alliance, a joint effort, involving the development of several drugs aimed at treating type 1 and type 2 diabetes patients.
“This study provides evidence that hormonal contraceptive methods may increase a woman’s risk for GDM (gestational diabetes) in her following pregnancy, even after adjusting for maternal age, race, education and income level, marital status, Medicaid status at delivery, and type of prenatal care received,” the researchers wrote in the study, released today by the Centers […]
The oral medicine metformin (brand name Glucophage and others) is more effective at controlling blood glucose levels in African-Americans than in whites, according to new research published in The Journal of Endocrinology and Metabolism.
Results from dulaglutide’s sixth AWARD trial showed once-weekly dulaglutide 1.5mg was non-inferior to once-daily liraglutide 1.8mg when compared to metformin
Tapentadol-ER is a schedule II opioid analgesic that is commonly used for the treatment of moderate to severe chronic pain. It is unique in its dual acting mechanism in which it works as both a weak mu-opioid receptor agonist and a norepinephrine-reuptake inhibitor.
Diabetes patients stand to benefit from two experimental insulin therapies that could eventually replace Sanofi’s global leader Lantus, according to results from large clinical trials
A Novo Nordisk drug, IDegLira which combines its long-acting insulin degludec with its type 2 diabetes treatment Victoza, maintained superior blood sugar reduction after one year.
“…Sanofi will tap into technology advances that aim to create holistic treatment solutions which take into account the individual patient’s needs,” Pascale Witz, Sanofi’s executive vice president of global divisions and strategic development, said in the statement.
The discovery of sodium-glucose co-transporter 2 (SGLT2) inhibitors, with a novel mechanism independent of insulin secretion or sensitization, offered a new therapeutic approach for the management of type 2 diabetes mellitus.
Among diabetes patients receiving metformin, the addition of insulin compared with a sulfonylurea was associated with an increased risk of nonfatal cardiovascular outcomes and all-cause death
In experiments reported in the journal Proceedings of the National Academy of Sciences, the researchers tease out the mechanism behind metformin’s age-slowing effects: the drug causes an increase in the number of toxic oxygen molecules released in the cell and this, surprisingly, increases cell robustness and longevity in the long term.